Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

The VAPARA Study: Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

The purpose of this study is to verify and validate the intrinsic diagnostic value in terms of sensitivity and specificity of proteomic profiles determined during a pre-study for discriminating between allergy related asthma and allergy related rhinitis.

Inclusion Criteria:

• signed consent
• never-smokers or non-smoking for at least 2 years + < 5 packs per year
• capable of understanding the study
• patient is affiliated with a social security system
• positive skin tests (at least one for Montpellier region pneumoallergens)
• treated with nasal or inhaled corticoids, leucotriene receptor antagonists, anti-IgE, Theophylline, anti-histamines, sodium cromoglycate, beta-blockers, benzodiazépine, oral corticoids: all these treatments must be interrupted for at least 72 hours

Exclusion Criteria:

• Co-morbidities: none; no co-morbidities are accepted
• dental infections (any) during the 3 months preceding the study
• suspected alcoholism or drug abuse
• chronic viral infection (hepatitis, HIV)
• patient under guardianship